@article { author = {}, title = {Positive Effects of Oral β-Glucan on Mucositis and Leukopenia in Colorectal Cancer Patients Receiving Adjuvant FOLFOX-4 Combination Chemotherapy}, journal = {Asian Pacific Journal of Cancer Prevention}, volume = {15}, number = {8}, pages = {3641-3644}, year = {2014}, publisher = {West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.}, issn = {1513-7368}, eissn = {2476-762X}, doi = {}, abstract = {The present study aimed to determine the effect of oral β-glucan on mucositis and leukopenia in 62 consecutivepatients with colorectal cancer treated with an adjuvant FOLFOX-4 regimen. The patients were retrospectivelyevaluated in 2 groups: one group received β-glucan and the other did not (control group). Leucocytes, neutrophils,and platelets were evaluated before and 1 week after chemotherapy and oral mucositis and diarrhea were noted.Leucocyte and neutrophil counts after chemotherapy in the β-glucan group were 7,300/mm3 and 3,800/mm3,respectively, and the reductions, as compared to baseline, were not significant (p=0.673 and 0.784). The medianplatelet count was 264,000/mm3 after chemotherapy in the β-glucan group and the reduction, as compared tobaseline, was borderline significant (p=0.048). In the control group, reduction in leucocyte, neutrophil, andplatelet counts was statistically significant. Oral mucositis and diarrhea were less common in the β-glucan group.We conclude that β-glucan can be used to reduce the adverse effects of chemotherapy.}, keywords = {β-glucan,Chemotherapy,neutropenia,Mucositis,colorectal cancer}, url = {https://journal.waocp.org/article_29133.html}, eprint = {https://journal.waocp.org/article_29133_3c7bc0eb51eef36fba4611caa843e5d3.pdf} }